Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned phase II trial of SPN 811 in patients with ADHD.

Trial Profile

Planned phase II trial of SPN 811 in patients with ADHD.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPN 811 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Supernus Pharmaceuticals

Most Recent Events

  • 13 Jul 2010 New trial record
  • 13 Jul 2010 This trial is expected to be initiated in 2011, according to a Supernus Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top